Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Obesity segment accounted for USD 10.52 Billion in 2025, representing 28% share of the GLP-1 Drug Market, and is expected to grow at a CAGR of 29.4% driven by increasing obesity prevalence and rising awareness of weight management therapies
Its anti-inflammatory and antioxidant properties are well known qualities and promotes the synthesis of elastin and collagen
This action marks the drug as the first-ever generic glucagon-like peptide-1 (GLP-1) receptor agonist indicated for adults with obesity or overweight who also have a weight-related medical problem and pediatric patients aged 12 to 17 years with a weight greater than 60 kg and obesity specifically to aid weight loss and keep the weight off
Oral Diseases, 30 (8), 51605174
Designed for use in strictly controlled in vitro and preclinical models
